Aortic valve prosthesis On-X®

metallic

The only aortic mechanical valve with FDA, Health Canada, and CE Mark approval for Low INR of 1.5 – 2.0.1* Clinically proven to be safer with less anticoagulation resulting in 87% reduction in bleeding, with no increase in thromboembolism and no valve thrombosis.2* Unique material and design provide optimal hemodynamics compared with other mechanical and bioprosthetic aortic valves at ≥1 year. 1,3-7   *Reduce INR after 3 months of standard therapy.1 Clinical Evidence 87% Lower Bleeding Risk with 50% Lower INR1 The On-X Aortic Heart Valve Post Approval Study (PAS) 5-year interim data determined that in a real-world setting, the On-X Aortic Valve managed at a low INR of 1.5-2.0 demonstrates an 87% reduction in major bleeding (MB) with no increase in thromboembolism (TE) and no valve thrombosis (VT) when compared to standard INR of 2.0-3.0.*1 All other mechanical aortic valve anticoagulation should be managed at an INR of 2.0-3.0.2 *Reduce INR after 3 months post-operative standard therapy.4 OPTIMAL HEMODYNAMICS The On-X Aortic Valve provides optimal mean gradients compared with other bileaflet and bioprosthetic aortic valves at ≥1 year.4-9